{
    "clinical_study": {
        "@rank": "84172", 
        "acronym": "FIRINOX", 
        "arm_group": {
            "arm_group_label": "Optimal chemotherapy courses", 
            "arm_group_type": "Experimental", 
            "description": "Neoadjuvant chemotherapy 4 courses of FIRINOX early 5 patients, and 8 courses of FIRINOX subsequent 5 patients"
        }, 
        "brief_summary": {
            "textblock": "FOLFIRINOX regimen was recently presented at an international oncology meeting and\n      represents a new standard regimen in the treatment of metastatic pancreatic cancer.\n      FOLFIRINOX is one of the high response rate treatment regimen , the investigators considered\n      as a promising treatment as neoadjuvant chemotherapy . On the other hand , incidences of\n      grade 3 or 4 neutropenia , febrile neutropenia and diarrhea were significantly higher in the\n      FOLFIRINOX group compared with gemcitabine group. Therefore, it was decided to consider the\n      balance of safety and efficacy as a preoperative chemotherapy, the investigators use the\n      FIRINOX regimen by eliminating LV and bolus 5-FU, and irinotecan reduced to 150mg/m2 of\n      180mg/m2 from FOLFIRINOX regimen"
        }, 
        "brief_title": "Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Pancreatic Cancer.", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "FOLFIRINOX regimen was recently presented at an international oncology meeting and\n      represents a new standard regimen in the treatment of metastatic pancreatic cancer.\n      FOLFIRINOX is one of the high response rate treatment regimen , the investigators considered\n      as a promising treatment as neoadjuvant chemotherapy . On the other hand , incidences of\n      grade 3 or 4 neutropenia , febrile neutropenia and diarrhea were significantly higher in the\n      FOLFIRINOX group compared with gemcitabine group. Therefore, it was decided to consider the\n      balance of safety and efficacy as a preoperative chemotherapy, the investigators use the\n      FIRINOX regimen by eliminating LV and bolus 5-FU, and irinotecan reduced to 150mg/m2 of\n      180mg/m2 from FOLFIRINOX regimen. The investigators also evaluate the optimal treatment\n      schedule of FIRINOX therapy as neoadjuvant chemotherapy, optimal duration between surgery\n      and chemotherapy, R0 resection rate, and resection rate for borderline resectable pancreatic\n      cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologically proven invasive pancreatic ductal carcinoma\n\n          -  Cases that meet the definition of borderline resectable pancreatic cancer 1) or 2)\n\n               1. Definition of a borderline resectable pancreatic cancer is filledin NCCN\n                  guideline version 1.2014 pancreatic adenocarcinoma\n\n               2. Patients indicated distal pancreatectomy with en bloc celiac axis resection\n\n          -  PS (ECOG) 0-1\n\n          -  \u226720 years old and < 75 years old\n\n          -  First line treatment\n\n          -  The following criteria must be satisfied in laboratory tests within 14 days of\n             registration White blood cell count \u226612,000/mm3 Neutrophil count \u22671,500/mm3 Platelet\n             count \u2267100,000mm3 Total bilirubin \uff1c2.0mg/dL Serum Creatinine \u2266upper limits of\n             normal(ULN) AST, ALT\u22662.5\u00d7ULN Albumin\u22673.0g/dL Hemoglobin\u22679.0g/dL\n\n          -  Written informed consent to participate in this study\n\n        Exclusion Criteria:\n\n          -  Severe drug hypersensitivity\n\n          -  Multiple primary cancers within 5 years\n\n          -  Severe infection\n\n          -  With grade2 or more severe peripheral neuropathy\n\n          -  With intestinal paralysys, ileus\n\n          -  Interstitial pneumonia or pulmonary\n\n          -  With uncontrollable pleural effusion or ascites\n\n          -  Receiving atazanavir sulfate\n\n          -  With uncontrollable diabetes\n\n          -  With uncontrollable heart failure, angina, hypertension, arrhythmia\n\n          -  With severe psychological symptoms\n\n          -  With watery diarrhea\n\n          -  Pregnant or lactating women, or women with known or  suspected pregnancy\n\n          -  Inappropriate patients for entry on this study in the judgment of the investigator\n\n          -  With UGT1A1*28 and/or UGT1A1*6 polymorphisms"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02148549", 
            "org_study_id": "FIRINOX", 
            "secondary_id": "UMIN000013809"
        }, 
        "intervention": {
            "arm_group_label": "Optimal chemotherapy courses", 
            "description": "FIRINOX regimen by eliminating LV and bolus 5-FU, and irinotecan reduced to 150mg/m2 of 180mg/m2 from FOLFIRINOX regimen.", 
            "intervention_name": "FIRINOX", 
            "intervention_type": "Drug", 
            "other_name": "Oxaliplatin, Irinotecan, 5-FU."
        }, 
        "intervention_browse": {
            "mesh_term": "Irinotecan"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Borderline resectable pancreatic cancer", 
            "R0 resection", 
            "Resection rate", 
            "Optimal schedule"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Tsutomu Fujii, M.D., PhD."
                }, 
                "facility": {
                    "address": {
                        "city": "Nagoya", 
                        "country": "Japan", 
                        "state": "Aichi"
                    }, 
                    "name": "Nagoya University"
                }, 
                "investigator": {
                    "last_name": "Tsutomu Fujii, M.D., PhD.", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Hirochika Toyama, M.D., PhD."
                }, 
                "facility": {
                    "address": {
                        "city": "Kobe", 
                        "country": "Japan", 
                        "state": "Hyogo"
                    }, 
                    "name": "Kobe University"
                }, 
                "investigator": {
                    "last_name": "Hirochika Toyama, M.D., PhD.", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Masayuki Sho, M.D., PhD."
                }, 
                "facility": {
                    "address": {
                        "city": "Kashihara", 
                        "country": "Japan", 
                        "state": "Nara"
                    }, 
                    "name": "Nara Prefectual Medical University"
                }, 
                "investigator": {
                    "last_name": "Masayuki Sho, M.D., PhD.", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Sohei Satoi, M.D., PhD."
                }, 
                "facility": {
                    "address": {
                        "city": "Hirakata", 
                        "country": "Japan", 
                        "state": "Osaka"
                    }, 
                    "name": "Kansai Medical University"
                }, 
                "investigator": {
                    "last_name": "Sohei Satoi, M.D., PhD.", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Hiroaki Nagano, M.D., PhD."
                }, 
                "facility": {
                    "address": {
                        "city": "Suita", 
                        "country": "Japan", 
                        "state": "Osaka"
                    }, 
                    "name": "Osaka University"
                }, 
                "investigator": {
                    "last_name": "Hiroaki Nagano, M.D., PhD.", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Yoshiaki Murakami, M.D., PhD."
                }, 
                "facility": {
                    "address": {
                        "city": "Hiroshima", 
                        "country": "Japan"
                    }, 
                    "name": "Hiroshima University"
                }, 
                "investigator": {
                    "last_name": "Yoshiaki Murakami, M.D., PhD.", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ryosuke Amano, M.D., PhD."
                }, 
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan"
                    }, 
                    "name": "Osaka City University"
                }, 
                "investigator": {
                    "last_name": "Ryosuke Amano, M.D., PhD.", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Tatsuya Ioka, M.D., PhD."
                }, 
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan"
                    }, 
                    "name": "Osaka Medical Center for Cancer and CVD"
                }, 
                "investigator": {
                    "last_name": "Tatsuya Ioka, M.D., PhD.", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ken-ichi Okada, M.D., PhD."
                }, 
                "facility": {
                    "address": {
                        "city": "Wakayama", 
                        "country": "Japan", 
                        "zip": "641-8510"
                    }, 
                    "name": "Wakayama Medical University"
                }, 
                "investigator": {
                    "last_name": "Hiroki Yamaue, M.D., PhD.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Pilot Study of Neoadjuvant Chemotherapy of FIRINOX for Patients With Borderline Resectable Pancreatic Cancer", 
        "overall_contact": {
            "email": "yamaue-h@wakayama-med.ac.jp", 
            "last_name": "Hiroki Yamaue, M.D., Ph.D.", 
            "phone": "+81-73-441-0613"
        }, 
        "overall_official": {
            "affiliation": "Wakayama Medical University", 
            "last_name": "Hiroki Yamaue, M.D., PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Toxicities will be assessed according to Common Terminology Criteria for Adverse Events (CTCAE) 4.0.", 
            "measure": "Number of participants with toxicity of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.", 
            "safety_issue": "No", 
            "time_frame": "Up to 30 weeks."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02148549"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Wakayama Medical University", 
            "investigator_full_name": "Hiroki Yamaue", 
            "investigator_title": "Dean & Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "The resection rate of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks."
            }, 
            {
                "measure": "The R0 resection rate of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 weeks."
            }, 
            {
                "measure": "The optimal treatment schedule of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years."
            }
        ], 
        "source": "Wakayama Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wakayama Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}